IntraBio files first-ever FDA application for an Ataxia-Telangiectasia drug with AQNEURSA sNDA submission

IntraBio Inc., a privately held Austin, Texas-based biopharmaceutical company specialising in rare and neurological disease therapies, submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) on 20 March 2026 seeking approval of levacetylleucine for the treatment of Ataxia-Telangiectasia, a rare and invariably progressive inherited neurodegenerative disorder for which no approved therapy exists anywhere in the world. The application, which seeks to expand the existing label of AQNEURSA beyond its current approval in Niemann-Pick disease type C, is the first regulatory filing ever submitted to the FDA for an A-T treatment. The submission is supported by a pivotal Phase III randomised controlled trial that met its primary endpoint and key secondary endpoints with high statistical significance, establishing the largest and most rigorously controlled efficacy dataset in A-T to date. For a condition that robs children of motor function before they reach adulthood and leaves families with no pharmacological options, the filing marks a material turning point in a disease area that has been clinically dormant for decades.

Why is IntraBio using the supplemental NDA pathway rather than a standalone application for Ataxia-Telangiectasia?

The supplemental NDA route is available when a sponsor already holds an approved application for a drug product at the FDA, and IntraBio’s position is straightforward: AQNEURSA received FDA approval for the neurological manifestations of Niemann-Pick disease type C in adults and pediatric patients weighing at least 15 kg, and that approved application forms the regulatory foundation on which the A-T expansion is built. This matters because the sNDA pathway allows IntraBio to reference the established safety dossier, manufacturing controls, and clinical pharmacology data already on file, rather than constructing a full New Drug Application from the ground up. The practical consequence is a leaner submission package and a cleaner benefit-risk narrative, since the agency is evaluating an incremental indication rather than an entirely novel compound.

There is a credibility dividend here as well. When a drug has already been approved in one rare neurological indication and the sponsor can demonstrate a biologically coherent rationale for extension into a second, FDA reviewers are working with familiar data rather than an unproven safety record. AQNEURSA’s safety profile in NPC, characterised by no drug-related serious adverse events and an adverse reaction profile limited to gastrointestinal events and upper respiratory infections, is precisely the kind of established track record that reduces uncertainty during supplemental review. That said, the FDA retains full discretion to refuse to file, to request additional data, or to reach a different benefit-risk conclusion for A-T despite the prior approval. Regulatory certainty is never guaranteed by precedent alone.

What did the pivotal Phase III trial actually demonstrate about levacetylleucine’s efficacy in Ataxia-Telangiectasia patients?

The pivotal IB1001-303 study, registered as NCT06673056, was a randomised, double-blind, placebo-controlled crossover trial enrolling pediatric and adult patients aged four years and older with a confirmed A-T diagnosis. Participants received levacetylleucine or placebo on top of standard of care for twelve weeks before crossing to the opposite arm. The primary endpoint was change from baseline on the Scale for the Assessment and Rating of Ataxia, known as SARA, which is the clinician-rated instrument used across ataxia trials to capture the severity of cerebellar dysfunction across gait, stance, speech, and limb coordination domains. IntraBio reported in January 2026 that the trial met this endpoint with high statistical significance, with clinically meaningful improvements recorded compared to placebo.

Secondary endpoints added further weight to the primary finding. The Investigator’s Clinical Global Impression of Improvement produced a mean improvement of 0.6 points on levacetylleucine versus 0.2 points on placebo, yielding a p-value of 0.02 and indicating that blinded investigators independently corroborated the SARA result. Subgroup analyses across all enrolled demographic segments showed consistent directional benefit, which IntraBio has characterised as evidence of broad applicability across the A-T population rather than a finding concentrated in a specific subgroup. The crossover design, while standard in rare disease trials where patient numbers are limited, introduces the theoretical risk of carryover effects between treatment periods, a methodological consideration that FDA reviewers are likely to scrutinise. The company has not publicly disclosed how it addressed this in the statistical analysis plan submitted with the sNDA.

How does the disease burden of Ataxia-Telangiectasia shape the commercial and regulatory stakes of this FDA filing?

Ataxia-Telangiectasia is caused by biallelic loss-of-function mutations in the ATM gene, which encodes a serine-threonine kinase with a central role in DNA damage detection and repair. The consequence of ATM dysfunction extends well beyond the cerebellum: affected individuals develop cerebellar atrophy leading to progressive gait ataxia, dysarthria, and oculomotor apraxia, and most require a wheelchair before reaching their teens. The systemic burden is severe, with immune deficiency resulting in recurrent and sometimes fatal infections, pulmonary complications, and a lifetime cancer risk estimated to be between 10 and 38 percent across published natural history studies, with lymphoid malignancies representing the most common oncological threat.

IntraBio has cited epidemiological estimates of approximately 4,600 diagnosed A-T patients in the United States and a comparable burden across Europe’s four largest markets. The disease affects roughly one in every 70,000 people. These are small numbers by any commercial standard, but in orphan drug economics, small patient populations combined with no existing approved therapy create the conditions for premium pricing and extended market exclusivity under both the Orphan Drug Act in the United States and equivalent frameworks in Europe. If AQNEURSA reaches approval for A-T, it would likely be the only approved pharmacological option in the indication for the foreseeable future, and pricing would reflect that scarcity. The commercial logic is straightforward even if the patient numbers are modest.

What is the mechanistic rationale connecting levacetylleucine’s NPC approval to its potential efficacy in Ataxia-Telangiectasia?

Levacetylleucine is the L-enantiomer of N-acetylleucine, an orally administered modified amino acid absorbed via monocarboxylate transporters. Its proposed mechanism of action in neurological disease centres on modulation of lysosomal function and cellular stress pathways, including effects on autophagy and membrane lipid homeostasis, which are disrupted across multiple rare neurodegenerative conditions. In Niemann-Pick disease type C, the primary pathophysiology involves intracellular cholesterol trafficking failure within lysosomes, producing secondary cerebellar neurodegeneration. In Ataxia-Telangiectasia, the primary driver is genomic instability from ATM loss-of-function, but the downstream consequences include oxidative stress, mitochondrial dysfunction, and lysosomal pathway dysregulation that overlap mechanistically with the NPC disease substrate.

This mechanistic overlap is the scientific foundation for IntraBio’s cross-indication platform thesis. The company is not merely expanding a drug into another rare disease opportunistically; it is testing a hypothesis that levacetylleucine’s pathway-level effects are relevant across a broader class of cerebellar and lysosomal conditions. The thesis is actively being extended further: IntraBio has announced plans to initiate a Phase III trial in CACNA1A-related disorders, which include Spinocerebellar Ataxia type 6 and Episodic Ataxia type 2, and is also conducting development in GM2 Gangliosidosis, which encompasses Tay-Sachs and Sandhoff disease. Each positive trial result reinforces the biological hypothesis and strengthens the company’s hand with regulators, partnering discussions, and any eventual capital-raising activity.

Is Quince Therapeutics pursuing a competing FDA application for Ataxia-Telangiectasia and how does EryDex compare to AQNEURSA?

IntraBio is not operating in a competitive vacuum. Quince Therapeutics is running a separate pivotal Phase III trial of EryDex in A-T, a formulation in which dexamethasone sodium phosphate is encapsulated within a patient’s own red blood cells using an ex vivo loading procedure before reinfusion. The Quince programme is focused on pediatric patients and evaluates the neurological effects of low-dose, sustained corticosteroid exposure delivered via this autologous erythrocyte carrier. If the trial reads out positively, Quince has publicly indicated it intends to file a New Drug Application with the FDA in 2026, which would potentially create a situation in which two mechanistically distinct A-T therapies are under simultaneous review for the first time.

The two programmes differ in practically every dimension that matters to prescribers and payers. AQNEURSA is an oral tablet dosed daily by patients or caregivers at home, applicable across both pediatric and adult populations with an established FDA approval history in a related indication. EryDex requires a specialised hospital-based procedure involving blood draw, ex vivo drug loading, and reinfusion on a periodic schedule, with the added complexity of patient-specific manufacturing. From a payer perspective, oral self-administration is categorically simpler and cheaper to reimburse than a cell-therapy adjacent procedure. From a patient and family perspective, the burden differential is material. Should both products ultimately receive approval, they are more likely to serve complementary segments of a small and heterogeneous patient population than to compete head to head for the same patients.

What regulatory timeline and review designations could accelerate or delay the AQNEURSA decision for Ataxia-Telangiectasia?

The FDA’s initial task following the sNDA submission is to conduct a filing review and determine whether the application is sufficiently complete to proceed to substantive review. A refuse-to-file decision would send IntraBio back to address identified gaps, resetting the clock. Assuming the filing is accepted, a standard review runs twelve months from the filing date, while a priority review designation compresses that to six months. Priority review is typically granted when a drug addresses a serious condition and offers potential for a substantial improvement over available therapy. Given that no approved therapy exists for A-T and the Phase III data showed statistically significant improvement on a validated functional scale, the conditions for priority review appear to be met, though the FDA makes this determination independently.

IntraBio may also hold or may be eligible for Breakthrough Therapy designation for the A-T indication, a status that provides more intensive FDA guidance during development and can further accelerate review. The company has not publicly disclosed its designation strategy for the A-T sNDA. Parallel EMA and global filings are also underway, and the EMA’s familiarity with levacetylleucine through the existing NPC marketing authorisation application, which remains under review with an opinion expected, provides a potentially favourable procedural context for the A-T application when it arrives in Europe. The coordination of multi-jurisdictional submissions simultaneously is standard practice for rare disease sponsors seeking to minimise time-to-access gaps across geographies.

What does the IntraBio platform strategy signal about where rare neurology drug development is heading in the next three years?

IntraBio’s approach reflects a broader strategic logic that has become increasingly visible in rare disease drug development: use a single molecule with a plausible cross-indication biological mechanism to build a portfolio of orphan approvals rather than committing all resources to a single commercial target. The economics of this model are compelling. Each new orphan approval adds its own exclusivity period, its own pricing power, and its own advocacy community. The manufacturing investment is largely amortised across indications once the first approval is secured. And each successive clinical success raises the scientific credibility of the platform, making future trials easier to justify to regulators, patient groups, and capital providers.

The risk embedded in this strategy is equally worth naming. Rare disease trials are small, and small trials are volatile. The crossover design used in IB1001-303, while efficient, requires careful handling of carry-over effects and period effects in the statistical analysis. A different endpoint or a different patient population in the next indication could produce a different outcome even if the underlying mechanism is genuine. Regulatory agencies, particularly the FDA in the post-Accelerated Approval reform environment, are also applying greater scrutiny to clinical meaningfulness as distinct from statistical significance, and the gap between a statistically significant SARA improvement and a change that materially alters a patient’s daily function is a question reviewers will probe. IntraBio has built a genuinely sophisticated rare disease platform, and the A-T sNDA represents its most consequential regulatory moment to date.

Key takeaways: IntraBio’s AQNEURSA sNDA and what the first Ataxia-Telangiectasia FDA filing means for rare neurology

• IntraBio has submitted the first-ever FDA application for an Ataxia-Telangiectasia therapy, using the supplemental NDA pathway anchored to AQNEURSA’s existing Niemann-Pick disease type C approval, eliminating the need for a full de novo application.
• The pivotal IB1001-303 Phase III crossover trial met its SARA primary endpoint and the CGI-I secondary endpoint with high statistical significance, with consistent benefit across all patient subgroups and no drug-related serious adverse events.
• A-T affects approximately 4,600 diagnosed patients in the United States and a comparable number across Europe’s four largest markets, creating classic orphan drug economics: small population, no existing approved therapy, and conditions for premium pricing under exclusivity frameworks.
• The sNDA pathway carries execution risk: the FDA can refuse to file or request additional data, and the crossover design of the Phase III trial introduces methodological questions around carryover effects that reviewers are likely to scrutinise.
• Parallel submissions to the EMA and other global regulators are underway, positioning IntraBio to launch simultaneously across multiple markets if approvals are granted, which would be a commercially and strategically significant outcome for a company of its size.
• Quince Therapeutics is pursuing a competing A-T programme with EryDex, an autologous erythrocyte-encapsulated corticosteroid requiring hospital-based administration, which contrasts sharply with AQNEURSA’s oral self-administration profile and is likely to serve a different segment of the patient population rather than compete directly.
• IntraBio’s cross-indication platform thesis, now extending to CACNA1A-related disorders including Spinocerebellar Ataxia type 6 and Episodic Ataxia type 2, and to GM2 Gangliosidosis, is predicated on a shared lysosomal and cellular stress mechanism that each new positive trial strengthens or weakens.
• Priority review designation, if granted, would compress the FDA review timeline from twelve months to six months; IntraBio’s public disclosures have not confirmed whether it has applied for priority review or Breakthrough Therapy designation for the A-T sNDA.
• The filing signals a broader shift in rare ataxia drug development from natural history studies and supportive care toward validated Phase III trials with regulatory-grade endpoints, a structural change that will raise the evidentiary bar for future entrants in the space.
• For institutional observers, the A-T filing is the most consequential regulatory event in IntraBio’s history and a proof-of-concept test for the company’s platform approach; success would likely attract partnership interest, licensing discussions, or acquisition attention from larger biopharma players seeking rare neurology assets.